A detailed history of Algert Global LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Algert Global LLC holds 276,040 shares of EXEL stock, worth $9.15 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
276,040
Previous 276,352 0.11%
Holding current value
$9.15 Million
Previous $6.21 Million 15.35%
% of portfolio
0.19%
Previous 0.21%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.96 - $27.6 $6,851 - $8,611
-312 Reduced 0.11%
276,040 $7.16 Million
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $397,830 - $464,135
19,559 Added 7.62%
276,352 $6.21 Million
Q4 2023

Feb 14, 2024

SELL
$19.25 - $24.13 $454,300 - $569,468
-23,600 Reduced 8.42%
256,793 $6.16 Million
Q3 2023

Nov 13, 2023

BUY
$19.04 - $22.74 $638,030 - $762,017
33,510 Added 13.57%
280,393 $6.13 Million
Q2 2023

Aug 14, 2023

BUY
$18.17 - $20.48 $1.81 Million - $2.04 Million
99,660 Added 67.69%
246,883 $4.72 Million
Q1 2023

May 12, 2023

BUY
$16.3 - $19.41 $199,479 - $237,539
12,238 Added 9.07%
147,223 $2.86 Million
Q4 2022

Feb 13, 2023

BUY
$14.96 - $17.39 $271,673 - $315,802
18,160 Added 15.54%
134,985 $2.17 Million
Q3 2022

Nov 15, 2022

BUY
$15.68 - $22.27 $273,741 - $388,789
17,458 Added 17.57%
116,825 $1.83 Million
Q2 2022

Aug 15, 2022

SELL
$17.44 - $23.16 $10,638 - $14,127
-610 Reduced 0.61%
99,367 $2.07 Million
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $379,513 - $505,200
22,285 Added 28.68%
99,977 $2.27 Million
Q4 2021

Feb 14, 2022

SELL
$15.84 - $21.88 $364,161 - $503,021
-22,990 Reduced 22.83%
77,692 $1.42 Million
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $1.64 Million - $2.13 Million
100,682 New
100,682 $2.13 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.7B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Algert Global LLC Portfolio

Follow Algert Global LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.